COst–Effectiveness and Budget Impact of Lung Cancer Immunotherapy in South America: Strategies to Improve Access

Pedro Nazareth Aguiar(Sociedade Brasileira de Oncologia Clínica), Ramon Andrade de Mello(Universidade Nove de Julho), Hani M. Babiker, Jahan C. Penny‐Dimri(Monash University), Gilberto Lopes(University of Miami), Auro del Giglio(Faculdade de Medicina do ABC), Luke A. Perry(Monash University), Hakaru Tadokoro(Universidade Federal de São Paulo)
Immunotherapy
August 1, 2018
10.2217/imt-2017-0183
Cited by 18

Related Papers

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.4k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Methylene blue in photodynamic therapy: From basic mechanisms to clinical applications
|Photodiagnosis and Photodynamic Therapy|2005|910
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non–Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study
|Journal of Clinical Oncology|2022|334
The biology of cancer-related fatigue: a review of the literature
|Supportive Care in Cancer|2015|305